Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth

Blood (2010) 116 (21): 3142.

https://doi.org/10.1182/blood.V116.21.3142.3142

Published: 2010

Journal Articles

FGFR3 Associates with and Tyrosine-Phosphorylates p90RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation

Sumin Kang, Shannon Elf, Shaozhong Dong, Taro Hitosugi, Ailan Guo, Hong Ruan, Sagar Lonial, Hanna Khoury, Ifor Williams, Gerard Karsenty, André Hanauer, Ting-Lei Gu, Jing Chen

Blood (2008) 112 (11): 3722.

https://doi.org/10.1182/blood.V112.11.3722.3722

Published: 2008

Journal Articles

Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070.

Shaozhong Dong, PhD, Sumin Kang, PhD, Sagar Lonial, MD, Hanna Jean Khoury, MD, Jean Viallet, PhD, Jing Chen, PhD

Blood (2007) 110 (11): 2920.

https://doi.org/10.1182/blood.V110.11.2920.2920

Published: 2007

Journal Articles

p90RSK2 as a Therapeutic Target in Treatment of FGFR3-Expressing t(4;14) Multiple Myeloma.

Sumin Kang, PhD, Shaozhong Dong, PhD, Tinglei Gu, PhD, Ailan Guo, PhD, Michael S. Cohen, PhD, Sagar Lonial, MD, PhD, Petet Leif Bergsagel, MD, PhD, Jack Taunton, PhD, Roberto D. Polakiewicz, PhD, Jing Chen, PhD

Blood (2007) 110 (11): 253.

https://doi.org/10.1182/blood.V110.11.253.253

Published: 2007

Journal Articles

14–3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1–transformed hematopoietic cells

Shaozhong Dong, Sumin Kang, Ting-Lei Gu, Sean Kardar, Haian Fu, Sagar Lonial, Hanna Jean Khoury, Fadlo Khuri, Jing Chen

Blood (2007) 110 (1): 360–369.

https://doi.org/10.1182/blood-2006-12-065615

Published: 2007

Journal Articles

14-3-3 Integrates Pro-Survival Signals in Hematopoietic Cells Transformed by Diverse Leukemogenic Tyrosine Kinases, and Represents a Common Target.

Shaozhong Dong, PhD, Sumin Kang, PhD, Ting-lei Gu, PhD, Sean Kardar, Sagar Lonial, MD, H. Jean Khoury, MD, Fadlo Khuri, MD, Haian Fu, PhD, Jing Chen, PhD

Blood (2006) 108 (11): 1138.

https://doi.org/10.1182/blood.V108.11.1138.1138

Published: 2006

Journal Articles

FGFR3 Activates RSK2 To Mediate Hematopoietic Transformation through Both Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway.

Sumin Kang, PhD, Shaozhong Dong, PhD, Ting-lei Gu, PhD, Michael S. Cohen, Sagar Lonial, MD, H. Jean Khoury, PhD, D. Gary Gilliland, MD, PhD, Jack Taunton, PhD, Roberto D. Polakiewicz, PhD, Jing Chen, PhD

Blood (2006) 108 (11): 514.

https://doi.org/10.1182/blood.V108.11.514.514

Published: 2006

NARROW

Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth

FGFR3 Associates with and Tyrosine-Phosphorylates p90RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation

Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070.

p90RSK2 as a Therapeutic Target in Treatment of FGFR3-Expressing t(4;14) Multiple Myeloma.

14–3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1–transformed hematopoietic cells

14-3-3 Integrates Pro-Survival Signals in Hematopoietic Cells Transformed by Diverse Leukemogenic Tyrosine Kinases, and Represents a Common Target.

FGFR3 Activates RSK2 To Mediate Hematopoietic Transformation through Both Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway.

Email alerts

ASH Publications

American Society of Hematology

Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth

FGFR3 Associates with and Tyrosine-Phosphorylates p90RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation

Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070.

p90RSK2 as a Therapeutic Target in Treatment of FGFR3-Expressing t(4;14) Multiple Myeloma.

14–3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1–transformed hematopoietic cells

14-3-3 Integrates Pro-Survival Signals in Hematopoietic Cells Transformed by Diverse Leukemogenic Tyrosine Kinases, and Represents a Common Target.

FGFR3 Activates RSK2 To Mediate Hematopoietic Transformation through Both Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only